After confirming the expression of the TRAIL construct under the UBC promoter (Figure 7A) and the sensitivity of PyMT cancer cells to the TRAIL in vitro (Figure 7, B and C), the TRAIL was placed under the MMP14 promoter fragment in a lentiviral vector and was used for in vivo efficacy study in the intracranial PyMT model (Figure 7D). The gene discussed is MMP14; the disease is cancer.